IRDiRC is delighted to announce the appointment of new members to the Regulatory Scientific Committee (RSC).
- Daniel O’Connor, Executive Director Regulatory and Early Access Policy, The Association of the British Pharmaceutical Industry (UK)
- Anneliene Jonker, Assistant Professor in Rare Diseases Therapeutic Innovation, University of Twente (The Netherlands)
- Francesca Buttigieg, Regulatory Affairs Executive Director, RhyGaze AG
- Silvia Cerolini, Head of Strategy & Transformation, Sanofi (UK)
Established in 2022, the Regulatory Scientific Committee (RSC) was created to address regulatory gaps driven by the rapid pace of innovation in rare diseases and therapeutic development. It brings together international experts from across regulatory bodies, patient organizations, industry, academia, and non-profit sectors.
The RSC is driven by three key priorities:
- Contributing to IRDiRC Task Forces and Working Groups to strengthen the impact of regulatory science
- Fostering multi-stakeholder dialogue to advance regulatory harmonization and support clinical research
- Identifying and anticipating emerging regulatory challenges
More information: https://irdirc.org/rsc/